08:40 AM EDT, 10/20/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that its late-stage study comparing upadacitinib, or Rinvoq, with Humira in certain adult patients with moderate to severe rheumatoid arthritis met its primary and most secondary endpoints at week 12, with no new safety concerns.

The drugmaker said that a significantly higher number of patients who had an inadequate response or intolerance to a tumor necrosis factor inhibitor, excluding Humira, achieved low disease activity and remission with upadacitinib compared to those receiving Humira.

The company said the study showed that 43.3% of patients on upadacitinib reached a low disease activity score, compared to 22.4% on Humira.

Additionally, 28.4% of patients on upadacitinib achieved remission, versus 14.5% on Humira, it added.